Home

Lundbeck sites Contact Us

  • Switch to Serdolect
  • Prescribing Serdolect
  • Supportive Material
  • Publications
  • About Schizophrenia
You are here: Home » Publications » Excellent patient safety » Low all cause mortality

Low all cause mortality

The European sertindole safety and exposure survey: a follow-up study of 8600 patients.

Peuskens J et al. Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):804-11

The Sertindole Cohort Prospective (SCoP) study: rationale, design and methodology.

Peuskens J et al. Pharmacoepidemiol Drug Saf. 2008 May;17(5):425-33

Higher cardiovascular mortality with sertindole ADROIT: a signal not confirmed

Moore. Int J Psych Pract 2002;6(Suppl 1):S3-S9.

Published: 07/02/2007   Last updated: 18/05/2010
Print  
  • Publications
    • Efficacy
      • At least as effective as risperidone
      • As effective as haloperidol
      • Maintaining long-term efficacy
    • Excellent patient acceptability
      • Effective without sedation
      • EPS at placebo level
      • Weight-gain
    • Enables patients to function
      • Improvement in cognitive function
      • Maintaining sexual function
    • Excellent patient safety
      • Low all cause mortality
    • Other publications

Literature Search


 
  • Switch to Serdolect
  • Prescribing Serdolect
  • Supportive Material
  • Publications
  • About Schizophrenia

www.irecover.com www.cipralex.com www.azilect.com www.serdolect.com www.depnet.com Disclaimer

H. Lundbeck A/S - Ottiliavej 9 - DK-2500 Copenhagen Valby - Phone +45 3630 1311 - Contact us

Lundbeck logo